| Document |
Document Title |
|
WO/2021/113682A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/113662A2 |
Dendrimer compositions and methods for the treatment of one or more inflammatory and/or angiogenic diseases and/or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the...
|
|
WO/2021/112240A1 |
The present invention pertains to: a composition in which olopatadine exists stably in a dissolved state; and a manufacturing method for the composition.
|
|
WO/2021/112597A1 |
The present invention relates to a pharmaceutical composition for treating diabetic retinopathy. According to the present invention, the pharmaceutical composition can treat diabetic retinopathy by means of a single administration and th...
|
|
WO/2021/113686A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/112254A1 |
[Problem] To provide a technique of producing a gelatin sponge, capable of improving the healing rate of therapy of a perforated eardrum using a gelatin sponge carrying a basic fibroblast growth factor. [Solution] This production method ...
|
|
WO/2021/107033A1 |
The purpose of the present invention is to provide a pharmaceutical composition having a high storage stability. This pharmaceutical composition comprises 0.0005-0.05 w/v% inclusive of glucose, a nonionic surfactant and an alkyldiaminoet...
|
|
WO/2021/107035A1 |
The purpose of the present invention is to provide a pharmaceutical composition for a soft contact lens, in which the adsorption of alkyldiaminoethylglycine onto the soft contact lens is suppressed. The pharmaceutical composition for a s...
|
|
WO/2021/108530A1 |
Aspects of the disclosure relate to a recombinant adeno-virus encoding an anti- Vascular endothelial cell growth factor (VEGF) agent in a cell or subject (e.g., rAAV2.7m8-KH902). In some embodiments, compositions described herein are use...
|
|
WO/2021/105509A1 |
A chimeric opsin GPCR protein comprising a light- sensitive upstream opsin portion and a target GPCR portion comprising a chimeric CT is provided that expresses strongly and is targeted into the correct subcellular compartment of target ...
|
|
WO/2021/107106A1 |
Provided is an oral composition for alleviating eye conditions. The present invention involves preparing an oral composition containing α-lipoic acid, an oral composition containing lutein and α-lipoic acid, a lutein flavor improver ...
|
|
WO/2021/059267A9 |
Pharmaceutical compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related and trauma- induced disorders, particularly of the eye, are provided.
|
|
WO/2021/108255A1 |
Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding por...
|
|
WO/2021/107692A1 |
As an invention relating to a pharmaceutical composition comprising mesenchymal stem cell-derived exosomes for prevention or treatment of an optic nerve disease, the present invention provides exosomes exhibiting a better effect of regen...
|
|
WO/2021/105857A1 |
Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or...
|
|
WO/2021/107122A1 |
The present disclosure provides an inhibitor of a hypoxia-inducible factor (HIF). The HIF inhibitor has low cytotoxicity and may be suitable for ophthalmic treatment. In the present specification, provided is a composition which is for...
|
|
WO/2021/107023A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, and specifically, an orexin type-2 receptor, said agent containing a novel compound having a urea skeleton or a ph...
|
|
WO/2021/107034A1 |
The purpose of the present invention is to provide a medicinal composition for soft contact lenses which contains an alkyldiaminoethylglycine inhibited from being adsorbed onto soft contact lenses. This medicinal composition for soft con...
|
|
WO/2021/099977A1 |
The present invention relates to a process for the preparation of crosslinked hyaluronic acid butyrate or crosslinked hyaluronic acid butyrate-formate or an acceptable salt thereof, wherein the process comprises the crosslinking reaction...
|
|
WO/2021/101344A1 |
The present invention relates to an eye drop preparation comprising an active ingredient selected from a 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol compound or a pharmaceutically acceptable salt thereof. The eye drop preparation ...
|
|
WO/2021/100940A1 |
The present invention relates to a composition for preventing, treating, or ameliorating macular degeneration, containing a Prunella vulgaris extract as an active ingredient. Specifically, the Prunella vulgaris extract of the present inv...
|
|
WO/2021/099909A1 |
A soft contact lens (4) comprises a solid component, which is based on a polymer, and a liquid component which is distributed in the solid component and which comprises at least one compound which is selected from vitamin E, vitamin B2 a...
|
|
WO/2021/097524A1 |
The present inventors have developed printable collagen bioinks using unmodified type I collagen with mechanical and structural properties that facilitate application to tissue in a structured form. In particular, the compositions of the...
|
|
WO/2021/099420A1 |
The present invention relates to synthetic retinal ON-bipolar cell-specific promoter sequences and their use in therapeutic transgene delivery to the eye for the improvement and/or restoration of vision. The invention features metabotrop...
|
|
WO/2021/094208A1 |
The invention relates to substituted imidazo pyrimidine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular di...
|
|
WO/2021/094209A1 |
The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in p...
|
|
WO/2021/093632A1 |
An active essence compounded with postbiotics, comprising the following raw materials in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of caprylic/capric/succinic triglyceride, 2.0-3.0% of sodium polyglutamate, 0.5-1.0% of Japa...
|
|
WO/2021/097306A1 |
Compositions, systems and methods for delivering CRISPR/Cas9-based genome editing system and a donor protein to a cell.
|
|
WO/2021/096330A1 |
The present invention provides a pharmaceutical composition for the prevention or treatment of ear disease, comprising a Castanopsis echinocarpa extract or fraction. In addition, the present invention provides a health functional food fo...
|
|
WO/2021/094210A1 |
The invention relates to substituted pyrazine carboxamide derivatives of formula (I) and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular...
|
|
WO/2021/092564A1 |
Provided herein are methods for generating cultivated autologous limbal epithelial cell grafts for the treatment of various disorders caused by limbal stem cell deficiency. This invention relates to methods and compositions for treating ...
|
|
WO/2021/092499A1 |
Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, ...
|
|
WO/2021/092470A1 |
The present disclosure relates to therapeutic compositions and therapies for use in the treatment of diseases and disorders of the eye. The present disclosure relates to curved, multilayer controlled-release ocular implant devices which ...
|
|
WO/2021/091718A1 |
This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration. The methods involve administration of ...
|
|
WO/2021/090911A1 |
Provided are: a method for selectively killing protein aggregate-containing cells; a kit therefor; a therapeutic drug for protein misfolding diseases; and a drug product for removing protein aggregates from a blood product. The method fo...
|
|
WO/2021/084021A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an COCH associated condition.
|
|
WO/2021/084522A1 |
The invention relates to topical ophthalmic preparations in eye drops containing bimatoprost as an active ingredient at the concentration of 0.1 mg/ml, wherein the presence of benzalkonium chloride is limited to the indispensable minimum...
|
|
WO/2021/087360A1 |
Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be direct...
|
|
WO/2021/086077A1 |
The present invention relates to an isoquinolinone derivative, a preparation method therefor, and a pharmaceutical composition, comprising same as an active ingredient, for prevention or treatment of a poly(ADP-ribose)polymerase-1 (PARP-...
|
|
WO/2021/087408A1 |
Provided herein are methods for preventing and/or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.
|
|
WO/2021/081826A1 |
Disclosed are applications of a PTBP1 inhibitor in preventing and/or treating retinal diseases. Specifically, provided are uses of an inhibitor of PTBP1 gene or an encoded protein thereof, for use in preparing a composition or preparatio...
|
|
WO/2021/084013A1 |
New treatment regimen for the treatment of neurological diseases or conditions It relates to a compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either...
|
|
WO/2021/081348A1 |
The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more CFI mutations.
|
|
WO/2021/080206A1 |
The present invention provides a composition containing a sweet potato stem and/or leaf extract for prevention, alleviation, or treatment of an ear disease. The composition according to the present invention can suppress hearing loss by ...
|
|
WO/2021/081206A1 |
Neurotrophin receptor binding conjugate compositions for delivering an active agent to nerve cells are provided. Conjugate compositions of the present disclosure according to certain embodiments include a one or more active agent compoun...
|
|
WO/2021/079536A1 |
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting o...
|
|
WO/2021/079962A1 |
A problem addressed by the present invention is to provide a pharmaceutical composition for the prevention and/or treatment of hearing loss. The present invention relates to a pharmaceutical composition for the prevention and/or treatm...
|
|
WO/2021/079986A1 |
A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group ...
|
|
WO/2021/079435A1 |
This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacterioph...
|
|
WO/2021/079984A1 |
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...
|
